Approvals, filings, CRLs, breakthrough designations and advisory committees.
The FDA has approved the first heart valve designed to dynamically expand in children. The source provides headline-level information only, without details such as the manufacturer's name, trial data, or indications.
Why it matters: Heat: 3 sources reported the same event
The American College of Physicians issued a clinical guideline in Annals of Internal Medicine recommending estrogen plus progestogen for females with a uterus, or estrogen alone for those without, as first-line treatment of menopausal vasomotor symptoms (hot flashes and night sweats), which affect up to 80% of females. For those with contraindications or intolerance to estrogen, ACP suggests an SNRI (desvenlafaxine or venlafaxine) as second-line treatment, then an SSRI, gabapentin or an NKra (elinzanetant or fezolinetant) as third-line. It urges clinicians to ask patients about vasomotor symptoms and weigh benefits, harms, cost and access in shared decisions.
Why it matters: New ACP guideline sets a ranked order for hormonal and nonhormonal treatment of menopausal vasomotor symptoms.
The FDA has posted a resource center for ICH M15, a guidance on general principles for model-informed drug development (MIDD). The guidance describes MIDD principles, including planning, model evaluation and evidence documentation, sets a harmonized framework for assessing MIDD-derived evidence, and gives recommendations on MIDD-related regulatory interactions, reporting and submission. FDA recommends sponsors use it when preparing meeting requests, background packages and regulatory submissions.
Why it matters: FDA now expects ICH M15 principles to shape MIDD evidence in submissions and meetings.
The FDA has issued application instructions for its Expedited IND Pilot Program. Sponsors and prospective Qualified Research Institutions each complete a form, then the sponsor submits both through the FDA ESG Gateway as one package. The application window stays open for 45 days with possible extension, and FDA scientific experts will review submissions and select 8 to 10 Sponsor-QRI pairs. Participating parties must form their business relationship outside FDA, which will only confirm that an official agreement exists.
Why it matters: FDA sets out how sponsors and QRIs apply for the Expedited IND Pilot Program and how many pairs will be selected.
The Nobel Prize in Physiology or Medicine went to Peter Hegemann, Georg Nagel and Karl Deisseroth for optogenetics, a light-based method for studying neurons. Alector licensed its preclinical Parkinson's therapy AL050 to Roche's Genentech for $100 million in guaranteed cash and up to $1.17 billion in milestones plus royalties. Separately, the FDA approved Lilly's Jaypirca as a first-line treatment for CLL or SLL patients without a 17p deletion.
Why it matters: Nobel recognition for optogenetics and a sizeable Roche-Alector brain drug deal matter to neuroscience-focused readers.
The FDA has approved Eli Lilly's Jaypirca as a first-line therapy for chronic lymphocytic leukemia (CLL), according to STAT News. The approval moves Jaypirca, already known in CLL treatment discussions, into the earlier-line setting. Details of the decision are behind the STAT+ paywall, with further coverage available to subscribers.
Why it matters: First-line CLL approval expands the eligible patient population for Lilly's Jaypirca.
The FDA has approved Ultragenyx Pharmaceutical's gene therapy rebisufligene etisparvovec (Fayuvi) for paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. It is the first FDA-approved treatment option for this rare neurodegenerative lysosomal storage disorder.
Why it matters: First FDA-approved therapy for a rare neurodegenerative lysosomal storage disorder.
The FDA has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated CLL or SLL who lack a 17p deletion. The decision is supported by the Phase III BRUIN CLL-313 trial, in which 282 treatment-naive patients received pirtobrutinib or bendamustine plus rituximab; over a median follow-up of 28 months, pirtobrutinib showed a progression-free survival hazard ratio of 0.20, with median PFS not reached versus 33.5 months and an overall response rate of 94% versus 81%. Jaypirca is already listed in NCCN guidelines as a Category 1 preferred option in relapsed or refractory CLL/SLL after prior covalent BTK inhibitor therapy.
Why it matters: First-line approval expands Lilly's non-covalent BTK inhibitor into initial CLL/SLL treatment based on strong Phase III data.
On August 26, 2026, the FDA approved daraxonrasib (brand name RASONQUE), developed by Revolution Medicines, for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or are unsuitable for multi-drug combination systemic therapy. It is the first FDA-approved RAS(ON) inhibitor worldwide, extending direct RAS inhibition beyond a single mutation subtype to a broader molecular population.
Why it matters: First FDA approval of a RAS(ON) inhibitor shifts direct RAS targeting to a broader patient population.
On August 27, 2026, the FDA approved Priovant Therapeutics' LISRAYA (brepocitinib) 30 mg tablets for adults with dermatomyositis. The FDA described it as the first approved oral treatment option for the indication and the first targeted therapy, being a small molecule directed at JAK/TYK2. Octagam 10%, an intravenous immunoglobulin, had been approved for adult dermatomyositis in 2021.
Why it matters: First oral and first targeted therapy approved for adult dermatomyositis affects treatment options for clinicians.
The US FDA has approved a new indication for Eli Lilly's pirtobrutinib (100 mg and 50 mg tablets), announced October 2, as first-line treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have not received prior treatment and have no known 17p deletion. Pirtobrutinib is a highly selective, non-covalent BTK inhibitor, the first and only approved one, binding both wild-type and C481-mutant BTK.
Why it matters: FDA approval extends pirtobrutinib into first-line CLL/SLL, expanding use of the only approved non-covalent BTK inhibitor.
Novo Nordisk said on October 2 that FDA review of Mim8, its hemophilia A drug, has stalled. The company submitted the marketing application in September 2025 and had expected a decision in the third quarter of this year. The delay stems from an issue at a manufacturing facility, not from the drug itself.
Why it matters: A regulatory delay affecting a hemophilia A candidate, with the cause being manufacturing rather than the drug.
Edwards Lifesciences said on October 1, 2026 that the FDA has approved the AUTUS pulmonary valve, a size-adjustable valve designed for children with congenital heart disease that can expand as the child grows. Valve enlargement is done through minimally invasive transcatheter procedures, which may reduce the need for repeat open-chest surgeries that children traditionally face years after valve replacement.
Why it matters: FDA approval of a first-of-kind growth-adaptable pediatric valve affects congenital heart disease practice.
The FDA has approved Eli Lilly's BTK inhibitor Jaypirca for first-line treatment of chronic lymphocytic leukemia (CLL). The current feed provides only the headline and no further details on trials, dosing, or the basis for approval.
Why it matters: Heat: 4 sources reported the same event
The FDA has extended its review of Novo Nordisk's marketing application for Denecimig, a FIX/FX bispecific antibody, delaying a regulatory decision that had been expected in the third quarter of this year. Novo Nordisk filed the application in September after Denecimig received breakthrough therapy designation, and it still plans a commercial launch in the first half of next year. Roche's next-generation FIX/FX bispecific NXT007 has advanced to phase three trials.
Why it matters: Delayed FDA review of a breakthrough-designated haemophilia candidate shifts Novo Nordisk's launch timing.
Roche has submitted its BTK inhibitor fenebrutinib for marketing approval in multiple sclerosis and received priority review. Against teriflunomide, fenebrutinib cut annualized relapse rates in RMS by 51.1% and 58.5%, and versus Ocrevus it reduced risk of progression in PPMS by 12%. If approved, it would be the first BTK inhibitor cleared for both RMS and PPMS, offering a new option for the 1 million US multiple sclerosis patients.
Why it matters: Priority review filing could yield the first BTK inhibitor approved for both RMS and PPMS.
China's NMPA granted conditional approval on September 30, 2026 to Bristol Myers Squibb's iberdomide hydrochloride capsules (brand name Zanfu), a class 1 innovative drug, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulator. It is the first approved Cereblon E3 ubiquitin ligase modulator (CELMoD) drug worldwide; the US FDA granted accelerated approval to the same regimen in August 2026.
Why it matters: First CELMoD drug approved anywhere reaches China through NMPA conditional approval for multiple myeloma.
FDA approved Eli Lilly's pirtobrutinib (Jaypirca) on October 2, 2026 for adults with previously untreated CLL or SLL without 17p deletion. In the BRUIN CLL-313 trial of 282 patients randomized to pirtobrutinib or bendamustine plus rituximab, median PFS was not estimable with pirtobrutinib versus 33.5 months in the control arm (hazard ratio 0.20, p<0.0001) at a median follow-up of 28 months. The recommended dose is 200 mg orally once daily until progression or unacceptable toxicity.
Why it matters: FDA approval of pirtobrutinib moves the BTK inhibitor into first-line CLL/SLL treatment based on a 0.20 hazard ratio.
The FDA has approved Fayuvi (rebisufligene etisparvovec), a gene therapy developed by Ultragenyx Pharmaceutical, making it the first FDA-approved therapy for children with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The rare inherited disease progressively damages the brain and nervous system, causing children to gradually lose cognitive, speech and other developmental abilities over time.
Why it matters: First-ever FDA approval of a therapy for children with Sanfilippo syndrome type A.
The FDA has approved iberdomide for multiple myeloma on the basis of minimal residual disease negativity, the first approval for the disease to use that endpoint. Iberdomide also represents a new generation of targeted protein degraders, with several more potent cereblon E3 ligase modulators already in clinical development.
Why it matters: First myeloma approval based on MRD negativity and a new class of cereblon E3 ligase modulators advancing.
